PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer.

CONCLUSIONS: Both presented (89)Zr-cetuximab administration schedules are safe. The recommended dose for future trials is 60MBq, with a minimum time interval for scanning of 6days.
PMID: 28012793 [PubMed - as supplied by publisher]

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - December 20, 2016 Category: Radiology Authors: van Loon J, Even AJ, Aerts HJ, Öllers M, Hoebers F, van Elmpt W, Dubois L, Dingemans AC, Lalisang RI, Kempers P, Brans B, Winnepenninckx V, Speel EJ, Thunnissen E, Smits KM, Boellaard R, Vugts DJ, De Ruysscher D, Lambin P Tags: Radiother Oncol Source Type: research